TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03842696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: * HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~* Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and Marrow Transplant (BMT)
Description: Undergo allogeneic BMT according to local site institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (or cyclosporine)
Description: Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
Study: NCT04558177

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct current stimulator
Description: HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct current stimulator
Description: HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.
Study: NCT02197312

Intervention type: DEVICE
Group type: OTHER
Intervention: NobelProcera Bridge Shaded Zirconia
Study: NCT03770260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study: NCT03386981

Intervention type: OTHER
Intervention: blood and saliva tests
Description: Blood and saliva will be tested for: bone turnover markers, cytokines, chemokines, adipokines, myokines and hormones regulating bone and energy metabolism
Study: NCT03282656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
Description: single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
Study: NCT03732339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GILUPI CellCollector®
Description: Use of GILUPI CellCollector® to detect CTC
Study: NCT01760057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites
Study: NCT01109264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride injection
Description: d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
Study: NCT04388592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner (NP) Led Care Arm
Description: The NP will conduct baseline consultation visits with the participants and their caregivers (if applicable). They will then initiate treatment for the participant's symptoms as appropriate (ie: depression treatment for depressive symptoms, fatigue management strategies), connect to resources in the community as needed (ie: rehabilitation programs, home care support, psychologist support) to optimize functioning. There will be scheduled follow visits and/or phone calls with the NP at 3 and 6 months.
Study: NCT03021057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
Study: NCT04516746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% (n/V) saline for injection.
Study: NCT00095420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills training targeting children with autism
Description: Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills training of peers without autism
Description: Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
Study: NCT01393834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Description: Delay cord clamping for 30 seconds after birth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Milking of the cord
Description: Milking of the cord 4 times in 10 seconds
Study: NCT02908061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery Radical Cystectomy
Description: All surgeries will be performed in an open or laparoscopic fashion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery Radical Cystectomy
Description: All surgeries will be performed in an open or laparoscopic fashion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrapro mesh
Description: Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
Study: NCT02498925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
Study: NCT05953181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active surveillance
Description: Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active surveillance
Description: Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.
Study: NCT02081924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kisspeptin 0.1
Description: Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kisspeptin 0.3
Description: Participants will receive kisspeptin hormone at a dose rate of 0.3 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kisspeptin 1.0
Description: Participants will receive kisspeptin hormone at a dose rate of 1.0 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones.
Study: NCT04543396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: A training program designed to enhance core strength, stability, and function will be performed on the Tonal device. Training sessions will occur twice weekly for eight weeks. Performance of this program will be supervised by a designated and clinically trained research team member who will not conduct the statistical analysis and subsequently not be blinded to Group assignment. The program will last approximately 20 minutes in length and incorporate the a series of progressive exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: A training program designed to enhance core strength, stability, and function will be performed on the Tonal device. Training sessions will occur twice weekly for eight weeks. Performance of this program will be supervised by a designated and clinically trained research team member who will not conduct the statistical analysis and subsequently not be blinded to Group assignment. The program will last approximately 20 minutes in length and incorporate the a series of progressive exercises.
Study: NCT03767933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 10mg/kg, maximum 600mg; Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10mg/kg, maximum 600mg; Oral liquid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 10mg/kg, maximum 600mg; Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10mg/kg, maximum 600mg; Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10mg/kg, maximum 600mg; Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 15mg/kg, maximum 1000mg; Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 15mg/kg, maximum 1000mg; Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.05mg/kg, maximum 5 mg; Oral liquid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen placebo
Description: Oral liquid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen placebo
Description: Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen placebo
Description: Oral liquid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone placebo
Description: Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone placebo
Description: Oral liquid
Study: NCT03859024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: oxycodone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gabapentin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celebrex
Description: Celebrex tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: ibuprofen tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: ibuprofen tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone injection
Study: NCT04534075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsules containing either dietary fiber or placebo
Description: The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Capsules containing either dietary fiber or placebo
Description: The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.
Study: NCT03354949

Intervention type: OTHER
Intervention: Measurement of sitting postural control of the adult (MCPAA)
Description: The Adult Seated Postural Control Measure 2.0 (MCPAA 2.0) is a clinical evaluation tool for sitting postural control of adult clients using a locomotion aid. It thus allows the evaluation of the two variables inherent to the postural control sit, the alignment of body segments and the influence between movement and posture.~It can also be used to evaluate the changes in seated postural control due to changes over time or to an adaptation of the sitting posture.~Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~the speed of propulsion by a wheelchair.
Study: NCT04721860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward Locomotion Treadmill Training (BLTT)
Description: 12-training sessions of reverse treadmill training (no bodyweight support) over four weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Forward Locomotion Treadmill Training (FLTT)
Description: 12-training sessions of forward treadmill training (no bodyweight support) over tfour weeks.
Study: NCT03095495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Humidified High Flow Nasal Cannula
Description: HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated Humidified High Flow Nasal Cannula
Description: HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy (Low Flow Nasal Cannula)
Description: will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
Study: NCT03205800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-screw
Description: Placement of a mini-screw
Study: NCT04088877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participants will attend the exercise facility at Wellspring two times a week. Sessions are completed under the supervision of an exercise physiologist and the duration of each session ranges from 1.0 - 1.5 hours. Each session includes a warm up on an aerobic exercise machine, a full body progressive RET program followed by balance and stretching exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Sculpting Class
Description: The sculpting program will take place once a week for 2 hours over an 8-week period. Sessions will be themed around body image and facilitated by an artist and registered psychologist who will lead the group in art techniques and self-reflection, respectively. Each group session will focus on a theme related to body image, and the participants will have the opportunity to reflect through their art and social interactions with one another.
Study: NCT03679923

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM® brand eggshell membrane
Description: Dietary supplement for the support of joint health.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02363335

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: mixed meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roflumilast/Sitagliptin
Description: Both Roflumilast and Sitagliptin together

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: This is already known to increase GLP-1 \&amp; GIP secretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: This is already known to increase GLP-1 \&amp; GIP secretion
Study: NCT03678064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: 16 sessions total. Provided by study PT twice weekly for a period of 8 weeks
Study: NCT00095420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination treatment of social skills/education about autism
Description: The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual training
Description: Participants will receive the usual training offered in their local school districts.
Study: NCT03803293

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pharmacogenomic testing
Description: A comprehensive PGx interpretive report created by OneOme (www.oneome.com) provides information on how an individual patient's genes may affect medication response. OneOme utilizes algorithms and curated clinical PGx knowledge to generate a highly intuitive personalized report based on a patient's genomic results.
Study: NCT04247347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Training
Description: Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dementia Education
Description: An educational program designed to teach family caregivers about the characteristics, types, causes, and risk factors of dementia, as well as teach about health promotion, the stages of dementia, behavior changes, communicating with a family member with dementia, and caring for oneself. The content to be presented within an audiovisual format using a tablet computer follows recommendations and guidelines developed through research and by the Alzheimer's Association and the National Institute on Aging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training
Description: A cognitive-behavioral intervention presented within an audiovisual format using a tablet computer that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
Study: NCT04327206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%NaCl
Description: 0.9% Sodium Chloride Injection